ClinicalTrials.Veeva
Menu

Find clinical trials for Acute Myeloid Leukemia (AML) in Madrid, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Leukemia
Acute Myeloid Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Syndrome
Cancer

Acute Myeloid Leukemia (AML) trials near Madrid, MD, ESP:

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T)

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Other: Best Supportive Care (BSC)
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Madrid, Spain and 164 other locations

This is a phase 1b, multi-arm, open-label study of HDM201 in combination with MBG453 or venetoclax in subjects with AML or high-risk MDS.For...

Active, not recruiting
Acute Myeloid Leukemia (AML)
High-risk Myelodysplastic Syndrome (MDS)
Biological: MBG453
Drug: HDM201

Phase 1

Novartis
Novartis

Madrid, Spain and 8 other locations

The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of JNJ-75276617 in combination with AML directed ...

Enrolling
Leukemia, Myeloid, Acute
Drug: Azacitidine (AZA)
Drug: Cytarabine

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Madrid, Spain and 30 other locations

The purpose of this study is to determine the safety, tolerability, maximum tolerated doses (MTDs) and recommended Phase 2 doses (RP2Ds) of JNJ-74856...

Active, not recruiting
Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Drug: VEN
Drug: AZA

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Madrid, Spain and 19 other locations

Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute...

Enrolling
Relapsed or Refractory Acute Myeloid Leukemia
Drug: Tuspetinib
Drug: Venetoclax Oral Tablet

Phase 1, Phase 2

Aptose Biosciences

Pozuelo De Alarcón, Madrid, Spain and 33 other locations

two-part study to determine recommended phase 2 dose (RP2D) and schedule of GSK3745417 administration in participants with relapsed/refractory AML...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: GSK3745417

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Madrid, Spain and 10 other locations

This trial will seek to extend the preliminary findings of efficacy of MBG453 in combination with hypomethylating agents (HMA) by evaluating MBG453 i...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Venetoclax
Drug: MBG453

Phase 2

Novartis
Novartis

Madrid, Spain and 27 other locations

or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or i...

Enrolling
Acute Myeloid Leukemia
Drug: Quizartinib
Drug: Etoposide

Phase 1, Phase 2

Daiichi Sankyo
Daiichi Sankyo

Madrid, Spain and 36 other locations

when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Valencia, Valenciana, Spain and 108 other locations

\[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse w...

Enrolling
Acute Myeloid Leukemia
Drug: Venetoclax
Drug: Fludarabine

Phase 3

LLS PedAL Initiative, LLC

Madrid, Spain and 73 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems